BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05552976 (Mezigdomide in Relapsed or Refractory Multiple Myeloma): BVCT ex-ante prediction vs. reported outcome

On 4 Apr 2025, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 29 May 2026 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant (PFS) and commercially TBD (OS pending).

Clinical Trial

NCTID
NCT05552976
Acronym
SUCCESSOR-2
Drug Name
Mezigdomide
Drug MoA
cereblon E3 ligase modulator (CELMoD)
Drug Modality
small molecule
Drug Class
Best-In-Class
Therapeutic Area
Neoplasms
Indication
Relapsed or Refractory Multiple Myeloma
Human Patients
606
Sponsor
Bristol-Myers Squibb
Phase
Phase 3

Prediction of , index 1961

Prospective Prediction
Prediction Index
1961
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient additive clinical benefit to carfilzomib and dexamethasone (MeziKd) in OS moderately superior to carfilzomib + dexamethasone (Kd) slightly superior to belantamab mafodotin + pomalidomide + dexamethasone (BPd), slightly inferior to mezigdomide + bortezomib + dexamethasone (MeziVd))
Technical Prediction
SUCCESS (statistically significant additive clinical benefit to carfilzomib and dexamethasone (MeziKd) in ORR/PFS strongly superior to carfilzomib + dexamethasone (Kd), slightly superior to belantamab mafodotin + pomalidomide + dexamethasone (BPd), slightly superior to mezigdomide + bortezomib + dexamethasone (MeziVd))

Readout of

Prediction Validation
Readout Date
Prediction To Readout
420 days in advance
Readout Data Interpretation
mezigdomide + carfilzomib + dexamethasone (MeziKd) achieved statistically significant superior-to-Kd PFS (HR 0.48; p<0.0001); OS data pending
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant (PFS) and commercially TBD (OS pending)
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480/BMS-986348), Carfilzomib, and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-2
Phase
Phase 3
Status
Active not recruiting
Enrollment
606
Lead sponsor
Bristol-Myers Squibb
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
DRUG: Mezigdomide; DRUG: Carfilzomib; DRUG: Dexamethasone
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2023-01-10
Primary completion
2026-09-28
Completion
2029-07-25
Primary outcomes
  • Progression-free Survival (PFS) (Up to approximately 5 years)

NCT05552976 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials